Although impressive, these results suggest that there may be a new intermediate risk category with RS scores of 11 to 25 (previously 18 to 30) that now contain the majority of BC patients (67.3%) for which therapy decisions will have to rely on other considerations.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}